Navigation Links
Unraveling the genetic picture of lung cancer
Date:10/22/2008

HOUSTON -- (Oct. 23, 2008) -- A study seeking possible cancer genes elucidated the mutations and the genetic pathways activated in the most common form of lung cancer lung adenocarcinoma and could lead to improved diagnosis and treatment, said the director of the Baylor College of Medicine Human Genome Sequencing Center that played a major role in the project led by the National Human Genome Research Institute.

In the report that appears in the Oct. 23 issue of the journal Nature, a national consortium of researchers called the Tumor Sequencing Project identified 26 genes that play a significant role in the development of lung adenocarcinoma as well as cellular pathways involved in the lung cancer. The analysis, involving 188 patients, more than any previous study, allowed scientists to find mutations associated with sub-types of the lung cancer such as those among non-smokers.

Lung adenocarcinoma kills an estimated 1 million people worldwide each year. As many as 10 percent of people with the disease are non-smokers. It is one of the deadliest cancers in men and women with only about 15 percent of those whom it strikes surviving five years.

The findings highlight the complexity of the disease. Along with the work from other groups which included analysis of gene expression, the mutation study undertaken by the BCM genome sequencing center and colleagues promises to unlock many of the secrets of cancer itself.

"Clearly, much still remains to be discovered. We have just begun to realize the tremendous potential of large-scale, genomic studies to unravel the many mysteries of cancer," said Dr. Richard Gibbs, a co-author of the lung adenocarcinoma paper and director of the BCM Genome Sequencing Center.

In the study, members of the consortium sequenced key candidate genes from 188 tumor samples and matching non-cancerous tissue from the same person. This approach enabled the BCM researchers to identify mutations with unprecedented sensitivity. As a result, genes such as neurofibromatosis 1 and retinoblastoma 1, and several more that had been previously associated with other cancers, were discovered to be involved in this type of lung cancer.

"Our ability to detect cancer-causing genes with such great sensitivity enabled us to create the most comprehensive map ever of how this kind of tumor is able to defeat the body's defenses against cancer," said Dr. David Wheeler, an associate professor who led the BCM genome sequencing center analysis team. "These data are likely to have very near term impact on the way physicians think about treating lung cancer."

Some anti-cancer drugs used to treat other kinds of cancers may be useful in lung as well, the researchers noted.


'/>"/>

Contact: Glenna Picton
picton@bcm.edu
713-798-4712
Baylor College of Medicine
Source:Eurekalert

Related biology technology :

1. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
2. Response Genetics Reports Second Quarter 2007 Financial Results
3. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
6. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
7. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
8. Interleukin Genetics Announces Management and Board Appointments
9. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... Denmark , Feb. 3, 2016 Ascendis ... biotechnology company that applies its innovative TransCon technology to ... present at an upcoming investor conference.Event:2016 Leerink Partners Global ... NY Date:  , Wednesday, February 10, 2016 Time:  ... www.ascendispharma.com . --> An audio webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier ... the North American healthcare market. , Aerocom Healthcare, LLC will be based in ... will provide new pneumatic tube systems or expand existing systems within the U.S. ...
(Date:2/3/2016)... ... February 03, 2016 , ... Resilinc released ... and analyzes nearly 750 unique supply chain notifications and alerts generated by its ... Supply chain risk management practitioners subscribe to the EventWatch service to receive early ...
(Date:2/3/2016)... Buffalo, NY (PRWEB) , ... February 03, 2016 ... ... several new products to aid in the rapid development and ongoing quality control ... the Zika Virus outbreak is extremely high,” Dr. Gregory R. Chiklis, President and ...
Breaking Biology Technology:
(Date:1/8/2016)... ANGELES and MANCHESTER, United Kingdom ... ("BBI"), a developer of innovative sensor-based diagnostic products, today announced ... financed by new and existing investors.  Proceeds from the financing ... SEM Scanner , a hand-held device for detecting early-stage pressure ... Ireland after receiving CE Mark approval. ...
(Date:1/7/2016)... , Jan. 7, 2016 Various factors ... biopharmaceutical products such as biologics and biosimilars. Some ... reduce healthcare expenditure, growing demand for cost-effective alternatives, ... population. Biosimilars are similar versions of their corresponding ... to their quality, safety, and efficacy. The global ...
(Date:1/6/2016)... Calif. , Jan. 6, 2016 ... biometrics market, Frost & Sullivan recognizes MorphoTrak, LLC, ... 2015 North American Frost & Sullivan Company of ... contactless fingerprint scanning technology, Morpho Wave™ , has ... in the fingerprint biometrics market. Morpho Wave ...
Breaking Biology News(10 mins):